Cargando…
A review of treatment of Pompe disease in infants
The glycogen storage disease type II (GSD-II), or Pompe disease, is due to the deficit of lysosomal glycogen degradation enzyme acid α-glucosidase (GAA). In infants, Pompe disease is characterized by prominent hypotonia, muscle weakness, motor delay, feeding problems, and respiratory and cardiac ins...
Autores principales: | Chien, Yin-Hsiu, Hwu, Wuh-Liang |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721312/ https://www.ncbi.nlm.nih.gov/pubmed/19707330 |
Ejemplares similares
-
Development of Newborn Screening for Pompe Disease
por: Hwu, Wuh-Liang, et al.
Publicado: (2020) -
The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020) -
Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease
por: Chien, Yin-Hsiu, et al.
Publicado: (2013) -
Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017) -
A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Lee, Ni-Chung, et al.
Publicado: (2017)